FibroScan® by echosens
The non-invasive gold standard solution for comprehensive management of liver health
Advancing Liver Health Management for all.
Echosens is introducing the LHM platform, an innovative cloud-based solution which assists clinicians in providing accessible, comprehensive liver care for their patients.
The LHM platform is a digital solution with an ecosystem for continuous monitoring and proactive management of liver disease.
Automate the transfer of FibroScan® results to the LHM platform
to help you make data-driven decisions
Enhance examinations with FibroScan® with Scores
and interpretation tools
Access tools, resources, and clinical care pathways to help
monitor and manage liver disease
Echosens developed the LHM to provide a digital solution with an ecosystem to support clinical decisions for physicians.
Patient management
Scores interpretation
Enhancing FibroScan® liver disease assessment with biological markers.
Additional tools and resources
The LHM platform is currently available only in the United States and some European countries. You can contact us to know more.
Any institution or customer using an eligible FibroScan® device (FibroScan® 430 Mini-Mini+; FibroScan® 530 Compact; FibroScan® Expert 630) can have access to the LHM platform. Check your eligibility with us. Accessing the LHM requires a computer with Internet connection. Products in the FibroScan® range are class IIa medical devices according to Rule 10 of ANNEX VIII of Regulation EU 2017/745 (CE 0459) and are manufactured by Echosens™. FibroScan® devices are intended to provide: Liver stiffness measurements at a shear wave frequency of 50 Hz, liver ultrasound attenuation measurements (CAP: Controlled Attenuation Parameter) at 3.5 MHz and spleen stiffness measurements at a shear wave frequency of 100 Hz (FibroScan® 630 Expert only). These non-invasive devices are intended to aid clinical management, diagnosis, and monitoring of patients with confirmed or suspected chronic liver disease, as part of an overall assessment of the liver. FibroScan® devices may aid the healthcare professionals in the assessment of liver fibrosis, steatosis, and in determining the likelihood of cirrhosis, and its complications (FibroScan® 630 Expert only). They are used, in conjunction with other clinical and laboratory data, during liver assessment in patients with confirmed or suspected chronic liver disease. Examinations with FibroScan® devices shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies. Fast is an algorithm intended to aid in the diagnosis of active fibrotic Non-Alcoholic Steatohepatitis (NASH) in patients with suspected Non-Alcoholic Fatty Liver Disease (NAFLD). Fast is used, during liver assessment, in patient with suspected NAFLD. The following precautions must be observed when using Fast: LSM (also known as E) and CAP™ measurements must come from the same FibroScan® examination; There must be no more than 6 months between the FibroScan® examination and the blood sample necessary for AST assessment. Fast must not be used in the following situations : pregnancy, patients under 18 years old, chronic or acute liver diseases other than NAFLD, liver transplant patients, cardiac failure and/or significant vascular disease, confirmed diagnosis of active malignancy or other terminal disease, use of treatment inducing liver injury. Agile 3+ calculator is a tool for clinicians, computed from LSM (obtained from FibroScan® device), AST, ALT, platelets, diabetes status, age and gender, to aid in the identification of patients with suspicion of NAFLD as having advanced fibrosis. It was developed based on a pool of retrospective cohorts and published in peer-reviewed literature. Agile 4 calculator is a tool for clinicians, computed from LSM (obtained from FibroScan® device), AST, ALT, platelets, diabetes status and gender, to aid in the identification of patients with suspicion of NAFLD as having cirrhosis. It was developed based on a pool of retrospective cohorts and published in peer-reviewed literature. Fast, Agile 3+ and Agile 4 are presented as educational services intended for licensed healthcare professionals. While these scores are about specific medical and health issues,they are not a substitute for or a replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.
The non-invasive gold standard solution for comprehensive management of liver health
Seamless liver health assessment for all
Enhance FibroScan® liver disease assessment with biological markers
Identification of at-risk MASH patients